Ketamine treatment for refractory anxiety: A systematic review.
anxiety
anxiolytic
depression
ketamine
ketamine infusion
refractory anxiety
treatment-resistant depression
Journal
British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
revised:
11
04
2022
received:
27
10
2021
accepted:
13
04
2022
pubmed:
6
5
2022
medline:
14
9
2022
entrez:
5
5
2022
Statut:
ppublish
Résumé
There is a growing interest in the psychiatric properties of the dissociative anaesthetic ketamine, as single doses have been shown to have fast-acting mood-enhancing and anxiolytic effects, which persist for up to a week after the main psychoactive symptoms have diminished. Therefore, ketamine poses potential beneficial effects in patients with refractory anxiety disorders, where other conventional anxiolytics have been ineffective. Ketamine is a noncompetitive antagonist of the N-methyl-d-aspartate (NMDA) glutamate receptor, which underlies its induction of pain relief and anaesthesia. However, the role of NMDA receptors in anxiety reduction is still relatively unknown. To fill this paucity in the literature, this systematic review assesses the evidence that ketamine significantly reduces refractory anxiety and discusses to what extent this may be mediated by NMDA receptor antagonism and other receptors. We highlight the temporary nature of the anxiolytic effects and discuss the high discrepancy among the study designs regarding many fundamental factors such as administration routes, complementary treatments and other treatments.
Identifiants
pubmed: 35510346
doi: 10.1111/bcp.15374
pmc: PMC9540337
doi:
Substances chimiques
Anti-Anxiety Agents
0
Receptors, N-Methyl-D-Aspartate
0
Ketamine
690G0D6V8H
Types de publication
Journal Article
Review
Systematic Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4412-4426Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Références
Eur J Pharmacol. 1990 Aug 21;185(1):1-10
pubmed: 2171955
J Psychopharmacol. 2021 Feb;35(2):137-141
pubmed: 32900266
Pharmacol Rev. 2021 Apr;73(2):763-791
pubmed: 33674359
Front Hum Neurosci. 2016 Nov 29;10:612
pubmed: 27965560
Brain Behav Immun. 2017 Jan;59:260-264
pubmed: 27638184
J Palliat Med. 2010 Jul;13(7):903-8
pubmed: 20636166
Neuropharmacology. 2016 Jan;100:17-26
pubmed: 26211972
BMC Med Res Methodol. 2019 Nov 4;19(1):203
pubmed: 31684874
Annu Rev Pharmacol Toxicol. 2019 Jan 6;59:213-236
pubmed: 30296896
J Psychopharmacol. 2018 Jun;32(6):663-667
pubmed: 29561204
Int Clin Psychopharmacol. 2017 Jan;32(1):49-55
pubmed: 27643884
Schizophr Res. 2005 Jan 1;72(2-3):235-48
pubmed: 15560968
Am J Psychiatry. 2008 Mar;165(3):342-51
pubmed: 18172020
Curr Pain Headache Rep. 2021 Jul 16;25(9):57
pubmed: 34269883
J Trauma Stress. 1998 Jan;11(1):125-36
pubmed: 9479681
Ther Adv Psychopharmacol. 2020 May 18;10:2045125320922474
pubmed: 32523677
Org Lett. 2017 Sep 1;19(17):4572-4575
pubmed: 28829612
Nature. 2017 Jun 21;546(7659):E1-E3
pubmed: 28640258
CNS Neurosci Ther. 2013 Jun;19(6):381-9
pubmed: 23521979
Arch Gen Psychiatry. 2010 Aug;67(8):793-802
pubmed: 20679587
J Gen Physiol. 2018 Aug 6;150(8):1081-1105
pubmed: 30037851
Bipolar Disord. 2020 Dec;22(8):831-840
pubmed: 32406161
Dialogues Clin Neurosci. 2015 Jun;17(2):191-206
pubmed: 26246793
J Psychopharmacol. 2017 Oct;31(10):1302-1305
pubmed: 28441895
Depress Anxiety. 2019 Mar;36(3):235-243
pubmed: 30597688
J Palliat Med. 2013 Aug;16(8):958-65
pubmed: 23805864
CNS Spectr. 2020 Jun;25(3):331-342
pubmed: 31339086
World J Psychiatry. 2015 Dec 22;5(4):366-78
pubmed: 26740928
J Affect Disord. 2019 Dec 1;259:1-6
pubmed: 31430662
Int J Neuropsychopharmacol. 2019 Oct 1;22(10):665-674
pubmed: 31325908
Pharmacol Biochem Behav. 2014 Jan;116:137-41
pubmed: 24316345
J Clin Psychiatry. 2010 Aug;71(8):1047-54
pubmed: 20673545
Addiction. 2010 Jul;105(7):1154
pubmed: 20642504
Biol Psychiatry. 2018 Jan 1;83(1):2-4
pubmed: 29173705
Int J Neuropsychopharmacol. 2004 Jun;7(2):193-218
pubmed: 15003145
Anesthesiology. 1997 Apr;86(4):903-17
pubmed: 9105235
BMJ. 2016 Oct 12;355:i4919
pubmed: 27733354
Pharmacol Rev. 2018 Jul;70(3):621-660
pubmed: 29945898
Nature. 2016 May 04;533(7604):481-6
pubmed: 27144355
Depress Anxiety. 2019 Sep;36(9):801-812
pubmed: 31231925
Harv Rev Psychiatry. 2018 Nov/Dec;26(6):320-339
pubmed: 29465479
Am J Psychiatry. 2015 Oct;172(10):950-66
pubmed: 26423481
J Psychopharmacol. 2020 Mar;34(3):267-272
pubmed: 31526207
Front Neurosci. 2021 Apr 30;15:657714
pubmed: 33994933
Nature. 2021 Feb;590(7845):315-319
pubmed: 33328636
Neuropsychopharmacology. 2018 Jan;43(2):325-333
pubmed: 28849779
J Psychopharmacol. 2021 Feb;35(2):128-136
pubmed: 33040665
Science. 2012 Oct 5;338(6103):68-72
pubmed: 23042884
J Psychopharmacol. 2021 Feb;35(2):142-149
pubmed: 33427015
Neuropsychopharmacology. 2018 Jan;43(1):221-222
pubmed: 29192654
Eur J Pharmacol. 1997 Aug 20;333(1):99-104
pubmed: 9311667
Front Cell Neurosci. 2014 Nov 27;8:401
pubmed: 25505875
Br J Clin Pharmacol. 2022 Oct;88(10):4412-4426
pubmed: 35510346
Psychol Med. 2015 Dec;45(16):3571-80
pubmed: 26266877
Biol Psychiatry. 2000 Feb 15;47(4):351-4
pubmed: 10686270
Pharmaceuticals (Basel). 2010 Jan 06;3(1):19-41
pubmed: 27713241
Lancet Psychiatry. 2017 May;4(5):419-426
pubmed: 28395988
Ther Adv Psychopharmacol. 2020 May 11;10:2045125320916657
pubmed: 32440333
Br J Pharmacol. 2019 Dec;176 Suppl 1:S21-S141
pubmed: 31710717
Nat Rev Drug Discov. 2017 Dec;16(12):829-842
pubmed: 29075003
J Psychopharmacol. 2017 Oct;31(10):1306-1311
pubmed: 28922961
Mol Pharmacol. 2020 Sep;98(3):203-210
pubmed: 32606205
Biol Psychiatry. 2012 Jun 1;71(11):939-46
pubmed: 22297150
Eur J Pharmacol. 2010 Jan 10;626(1):49-56
pubmed: 19836379
Int J Neuropsychopharmacol. 2018 Aug 1;21(8):717-724
pubmed: 29718262